ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1029

Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea

Yoon-Kyoung Sung1,2, Kazuki Yoshida2,3, Femke H.M. Prince2,4, Michelle A. Frits2, Jung-Yoon Choe5, Won Tae Chung6, Jisoo Lee7, Eun-Mi Koh8, Dae-Hyun Yoo9, Simon M. Helfgott2, Nancy A. Shadick10, Michael E. Weinblatt11, Sang-Cheol Bae1 and Daniel H. Solomon2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, 4Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, 5Catholic University of Daegu School of Medicine, Daegu, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 7Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, 8Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 9Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 11Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ,

Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries, it is valuable to compare QOL measures across countries. The objective of this study was to compare health-related quality of life (HRQOL) of rheumatoid arthritis (RA) patients between United States (US) and South Korea.

Methods: Two year follow-up data on health and HRQOL measured with EuroQoL-5 dimension (EQ-5D) between 2009 and 2011 were compared between US-based (BRASS) and Korean-based (KORONA) cohorts. A total of 1,166 subjects (187 from BRASS and 979 from KORONA) were included in this study to compare the cross-sectional differences in QOL in 2009 and the longitudinal two-year change through 2011. We performed multivariate linear regression analyses to identify factors associated with QOL and its changes in each cohort. 

Results: The mean (standard deviation) of EQ-5D score (1.0 being the best possible score) of BRASS subjects was 0.82 (0.16) and that of KORONA subjects was 0.69 (0.25) (P <0.01) at baseline in 2009 (see table). Disease activity score (DAS) 28 (P<0.01) and modified health assessment questionnaire (MHAQ) score (P<0.01) were inversely associated high QOL in both cohorts. Income level (P<0.01) was positively and the number of comorbidities (P<0.01) was negatively associated with QOL only in KORONA (see table). Mean changes in QOL were not different between cohorts (P=0.17). Only changes in DAS28 and MHAQ during 2 years were significantly associated with the change in QOL in both cohorts.   

Conclusion: In this cross-national comparison study, changes in QOL and predictors for QOL were comparable between US-based BRASS and Korean-based KORONA, in spite of the differences in baseline characteristics and QOL level in each population.

Table. Multivariate linear regression analyses of predictors for utility score in 2009 and change until 2011

 

EQ-5D in 2009

ΔEQ-5D between 2009 and 2011

Cohort

BRASS (161)

KORONA (947)

BRASS (159)

KORONA (934)

R2(adjusted R2)

0.57 (0.53)

0.59 (0.58)

0.27 (0.21)

0.28 (0.27)

 

B (95% CI)

P

B (95% CI)

P

B (95% CI)

P

B (95% CI)

P

Intercept

0.77 (0.63~0.92)

<0.01

0.96 (0.85~1.07)

<0.01

0.11 (-0.07~0.30)

0.23

-0.12 (-0.25~0.02)

0.10

Age

0.001 (-0.001~0.003)

0.30

-0.0001 (-0.001~0.001)

0.83

-0.0009 (-0.003~0.001)

0.43

0.001

0.17

Disease duration

0.001 (-0.001~0.003)

0.22

0.0002 (-0.001~0.002)

0.79

0.0002 (-0.002~0.003)

0.88

0.001

0.46

Income

0.02 (-0.002~0.04)

0.07

0.03 (0.01~0.05)

<0.01

0.003 (-0.02~0.03)

0.80

-0.01 (-0.04~0.01)

0.28

Education

0.03 (-0.01~0.07)

0.09

-0.02 (-0.05~0.01)

0.19

-0.04 (-0.09~0.01)

0.13

0.03 (0~0.07)

0.07

Number of comorbidity

0.01 (-0.01~0.04)

0.32

-0.02 (-0.04~-0.01)

0.01

-0.02 (-0.05~0.02)

0.35

0.01 (-0.01~0.08)

0.54

Female

-0.01 (-0.05~0.04)

0.80

-0.03 (-0.06~0.002)

0.06

-0.01 (-0.07~0.04)

0.62

0.002 (-0.04~0.04)

0.93

Rheumatoid Factor

0.02 (-0.02~0.06)

0.28

0.01 (-0.03~0.04)

0.68

0.01 (-0.04~0.06)

0.68

0.03 (-0.01~0.08)

0.17

Biologic DMARD

0.03 (-0.004~0.07)

0.08

0.004 (-0.04~0.04)

0.85

-0.01 (-0.06~0.03)

0.63

-0.04 (-0.09~0.02)

0.17

NSAID

-0.02 (-0.05~0.02)

0.30

-0.004 (-0.03~0.02)

0.72

0.03 (-0.02~0.07)

0.21

0.02 (-0.01~0.04)

0.27

Steroid

-0.004 (-0.04~0.05)

0.86

-0.01 (-0.03~0.02)

0.50

-0.04 (-0.10~0.02)

0.17

-0.01 (-0.04~0.02)

0.58

DAS28-CRP

-0.04 (-0.05~-0.03)

<0.01

-0.05 (-0.06~-0.03)

<0.01

 

 

 

 

Modified HAQ

-0.18 (-0.24~-0.13)

<0.01

-0.35 (-0.38~-0.32)

<0.01

 

 

 

 

Δ DAS28-CRP

 

 

 

 

-0.03 (-0.04~-0.01)

<0.01

-0.04 (-0.05~-0.03)

<0.01

Δ Modified HAQ

 

 

 

 

-0.17 (-0.23~-0.10)

<0.01

-0.28 (-0.31~-0.24)

<0.01

*P<0.05; BRASS, Brigham Rheumatoid Arthritis Sequential Study; KORONA, KORean Observational study Network for Arthritis; OR, odds ratio; CI, 95% confidence interval; HAQ, health assessment questionnaire

Disclosure:

Y. K. Sung,
None;

K. Yoshida,
None;

F. H. M. Prince,
None;

M. A. Frits,
None;

J. Y. Choe,
None;

W. T. Chung,
None;

J. Lee,
None;

E. M. Koh,
None;

D. H. Yoo,
None;

S. M. Helfgott,

Abbott Laboratories,

5,

Genentech and Biogen IDEC Inc.,

5;

N. A. Shadick,
None;

M. E. Weinblatt,

MedImmune,

2,

Crescendo Bioscience, Inc.,

2,

Bristol Myers Squibb,

2,

MedImmune,

5,

Crescendo Bioscience, Inc.,

5,

Bristol Myers Squibb,

5;

S. C. Bae,

Regublic of Korea,

2,

Abbott Immunology Pharmaceuticals,

2,

Bristol-Myers Squibb,

2,

Eisai,

2,

GlaxoSmithKline,

2,

MSD,

2,

Pfizer Inc,

2;

D. H. Solomon,

Eli Lilly and Company,

2,

Amgen,

2,

Corrona,

2,

UpToDate,

7,

Pfizer Inc,

9,

Novartis Pharmaceutical Corporation,

9.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-of-life-in-rheumatoid-arthritis-cross-national-comparison-study-between-us-and-south-korea/